Effect of Homologous and Heterologous Booster in COVID-19 Vaccination

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2025 Jan 8

PMID 39770576

Authors

Marija Vukcevic

Mateja Despot

Aleksandra Nikolic-Kokic

Dusko Blagojevic

Milan Nikolic

Ana Banko

Tanja Jovanovic

Dragana Despot

Affiliations

Soon will be listed here.

Abstract

COVID-19 became a global health crisis in early 2020, and the way out of the crisis was the rapid development of vaccines by Sinopharm, Pfizer, and Sputnik, among others, which played a crucial role in controlling the pandemic. Therefore, this study aims to investigate the long-term immune response by measuring the levels of anti-S1 IgG antibodies induced by homologous and heterologous vaccination regimens. We investigated the titer of the anti-S1 IgG antibody produced for the viral surface antigen 3, 6 months after the second dose, before the third dose, and 1, 3, and 6 months after the third dose. Anti-S1 IgG antibody levels significantly increased three/six months after the second dose and following the booster in individuals without prior COVID-19 infection who received all three homologous vaccine doses. The group that initially responded poorly to Sinopharm showed a significant and sustained increase after receiving the Pfizer booster. Additionally, prior SARS-CoV-2 infection between primary and booster vaccination boosted anti-S1 antibody titers in all individuals, regardless of the vaccine used. The highest vaccine efficacy was observed during the primary vaccination period and declined over time, especially during the omicron-dominant period. The results suggest that while homologous and heterologous booster doses can significantly enhance anti-S1 IgG antibody levels, prior SARS-CoV-2 infection and the type of vaccine administered influence the duration and magnitude of the immune response.

References

Kanai D, Wakui H, Haze T, Azushima K, Kinguchi S, Kanaoka T . Improved Immune Response to the Third COVID-19 mRNA Vaccine Dose in Hemodialysis Patients. Kidney Int Rep. 2022; 7(12):2718-2721. PMC: 9464310. DOI: 10.1016/j.ekir.2022.09.005. View

Kuloglu Z, El R, Guney-Esken G, Tok Y, Talay Z, Barlas T . Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS-CoV-2: A longitudinal study. Allergy. 2022; 77(8):2459-2467. PMC: 9111385. DOI: 10.1111/all.15316. View

Money K, Baber U, Saart E, Samaan S, Sloane J . Blunted Post-COVID-19 Humoral Immunity in Patients With CNS Demyelinating Disorders on Anti-CD20 Treatments. Front Neurol. 2022; 13:843081. PMC: 8905651. DOI: 10.3389/fneur.2022.843081. View

Zhang Y, Ma X, Yan G, Wu Y, Chen Y, Zhou Z . Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. EClinicalMedicine. 2022; 54:101680. PMC: 9517939. DOI: 10.1016/j.eclinm.2022.101680. View

Markovic-Denic L, Popadic D, Jovanovic T, Bonaci-Nikolic B, Samardzic J, Tomic Spiric V . Developing COVID-19 vaccine recommendations during the pandemic: The experience of Serbia's Expert Committee on Immunization. Front Public Health. 2022; 10:1056670. PMC: 9713902. DOI: 10.3389/fpubh.2022.1056670. View

McMahan K, Yu J, Mercado N, Loos C, Tostanoski L, Chandrashekar A . Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2020; 590(7847):630-634. PMC: 7906955. DOI: 10.1038/s41586-020-03041-6. View

Richards K, Shannon I, Treanor J, Yang H, Nayak J, Sant A . Evidence That Blunted CD4 T-Cell Responses Underlie Deficient Protective Antibody Responses to Influenza Vaccines in Repeatedly Vaccinated Human Subjects. J Infect Dis. 2019; 222(2):273-277. PMC: 8494023. DOI: 10.1093/infdis/jiz433. View

Nordstrom P, Ballin M, Nordstrom A . Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022; 399(10327):814-823. PMC: 8816388. DOI: 10.1016/S0140-6736(22)00089-7. View

Mallah S, AlAwadhi A, Jawad J, Wasif P, Alsaffar B, Alalawi E . Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals. Vaccine. 2023; 41(12):1925-1933. PMC: 9868355. DOI: 10.1016/j.vaccine.2023.01.032. View

10.

Khong K, Zhang R, Hung I . The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What. Vaccines (Basel). 2022; 10(11). PMC: 9694140. DOI: 10.3390/vaccines10111924. View

11.

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020; 21(2):181-192. PMC: 7832443. DOI: 10.1016/S1473-3099(20)30843-4. View

12.

Taucher C, Lazarus R, Dellago H, Maurer G, Weisova P, Corbic-Ramljak I . Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3.... J Infect. 2023; 87(3):242-254. DOI: 10.1016/j.jinf.2023.06.022. View

13.

Viveiros-Rosa S, Mendes C, Farfan-Cano G, El-Shazly M . The race for clinical trials on Omicron-based COVID-19 vaccine candidates: Updates from global databases. Narra J. 2024; 2(3):e88. PMC: 10914133. DOI: 10.52225/narra.v2i3.88. View

14.

Zhang X, Xia J, Jin L, Wu Y, Zheng X, Cao X . Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis. Hum Vaccin Immunother. 2023; 19(2):2221146. PMC: 10288895. DOI: 10.1080/21645515.2023.2221146. View

15.

Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn H, Selvaraj M . Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022; 185(14):2422-2433.e13. PMC: 9181312. DOI: 10.1016/j.cell.2022.06.005. View

16.

Petrovic V, Vukovic V, Patic A, Markovic M, Ristic M . Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia. PLoS One. 2022; 17(2):e0263468. PMC: 8809561. DOI: 10.1371/journal.pone.0263468. View

17.

Kyaw M, Spinardi J, Zhang L, Oh H, Srivastava A . Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines. Hum Vaccin Immunother. 2023; 19(1):2165856. PMC: 9980688. DOI: 10.1080/21645515.2023.2165856. View

18.

Kanai D, Wakui H, Hanaoka M, Haze T, Azushima K, Shinoda S . Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis. Clin Exp Nephrol. 2023; 27(7):639-647. PMC: 10047466. DOI: 10.1007/s10157-023-02342-0. View

19.

Addetia A, Crawford K, Dingens A, Zhu H, Roychoudhury P, Huang M . Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 2020; 58(11). PMC: 7587101. DOI: 10.1128/JCM.02107-20. View

20.

Zheng X, Yang R, Zhao Y, Zhang Y, Yuan G, Li W . Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity. Virology. 2024; 594:110050. DOI: 10.1016/j.virol.2024.110050. View